NCT07850050
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below.
- Notable Recruitment opened
- Trial sites expanded: 16 → 46 locations
- Start date pushed from Oct 31, 2026 to Nov 25, 2026
- Minor Trial sites expanded: 13 → 16 locations
- Minor Trial sites expanded: 1 → 13 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage change in body weight from baseline to Week 52
Timeframe: At baseline and Week 52
Secondary (20)
Key secondary endpoint: Absolute change in IWQOL-Lite CT total scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT physical scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT physical function scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT psychosocial scale score (units on a scale) from baseline to Week 52
Absolute change in patient-reported outcome 1 from baseline to Week 52
Show 15 moreShow less
Absolute change in patient-reported outcome 2 frequency from baseline to Week 52
Absolute change in patient-reported outcome 2 severity from baseline to Week 52
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 52
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 52
Absolute change in PROMIS Physical Function score (PF-SF10a) (units on a scale) from baseline to Week 52
Absolute change in Body Mass Index (BMI) (kg/m2) from baseline to Week 52
Absolute in waist circumference (cm) from baseline to Week 52
Absolute change in systolic blood pressure (mmHg) from baseline to Week 52
Absolute change in Glycosylated Haemoglobin A1c (HbA1c) (%) from baseline to Week 52
Relative change in Low-Density Lipoprotein (LDL) cholesterol (%) from baseline to Week 52
Relative change in triglycerides (%) from baseline to Week 52
Relative change in High-Density Lipoprotein (HDL) (%) from baseline to Week 52
Relative change in non-HDL (%) from baseline to Week 52
Relative change in high sensitivity C-reactive protein (hsCRP) (%) from baseline to Week 52
Arms and interventions
Survodutide armExperimental
Placebo armPlacebo comparator
Combination products: Survodutide, Placebo
Sites
46 sites in 4 countries
United States 16, Germany 11, United Kingdom 11, Spain 8